Post
AstraZeneca ends Phase IV Andexxa trial after positive results
AstraZeneca has announced it would stop Andexxa’s Phase IV trial after the study achieved its aims earlier than expected. The ANNEXA-I …
EU agencies back Covid-19 vaccine update ahead of autumn campaign
Covid-19 vaccine compositions should be updated to provide protection against XBB Omicron variant strains in preparation for the autumn vaccination …
Baudax Bio reports promising additional data for neuromuscular blockade agent
Baudax Bio revealed has additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients …
ZyVersa Therapeutics inches closer to European patent approval for VAR 200
ZyVersa Therapeutics has received a notice of intention to grant from the European Patent Office for its patent application for …
Fosun Pharma and IFC to build new drug manufacturing plant in Africa
Shanghai Fosun Pharmaceutical (Group) is to collaborate with the International Finance Corporation (IFC) to construct a new pharmaceutical production facility …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
FDA accepts GSK’s sBLA for Jemperli to treat endometrial cancer
The US Food and Drug Administration (FDA) has accepted GSK’s supplemental biologics licence application (sBLA) for its Jemperli (dostarlimab) plus …
Acepodia raises funds to advance pipeline of cell therapies
Clinical-stage biotechnology company Acepodia has raised $100m in a Series D financing round to advance the first-in-class cell therapies being …
Eli Lilly achieving significant gains in obesity results
Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in …
US FDA expands approval for Merck’s PREVYMIS (letermovir)
The US Food and Drug Administration (FDA) has granted approval for a new indication for Merck’s PREVYMIS (letermovir) to prevent …
EC grants marketing authorisation for Fennec’s Pedmarqsi
The European Commission (EC) has granted marketing authorisation for Fennec Pharmaceuticals’ Pedmarqsi (sodium thiosulfate) to reduce the risk of hearing …
ASCO 2023: Ellipses Pharma advances plans for RET inhibitor following encouraging results
Chicago, Illinois-based Ellipses Pharma has announced its intention to accelerate the global clinical development of its selective RET inhibitor EP0031/A400. Following …
Who’s posting what? Virtual Care related social media posts increased by 21% in the pharma industry in Q1 2023
The global pharma industry experienced a 21% rise in social media posts on virtual care in Q1 2023 compared with …
Who’s posting what? Regenerative Medicine related social media posts increased by 11% in the pharma industry in Q1 2023
The global pharma industry experienced an 11% rise in social media posts on regenerative medicine in Q1 2023 compared with …
Who’s posting what? Orphan Designated Drugs related social media posts increased by 9% in the pharma industry in Q1 2023
The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared …
Who’s posting what? Microbiome related social media posts increased by 0.48% in the pharma industry in Q1 2023
The global pharma industry experienced 0.48% rise in social media posts on microbiome in Q1 2023 compared with the previous …